Benefits of CGM

Continuous glucose monitoring (CGM) provides real-time blood glucose measurements and reveals trends that enable proactive therapeutic interventions to maintain glycemic control.

 

CGM Advantages

Complete picture

The accuracy and frequency of CGM data allows clinicians to identify dangerous hypoglycemic and hyperglycemic excursions before they occur.

Real-time data

Shifting from intermittent glucose management to event-based glucose control can improve efficiency of glucose management in critically ill patients.

Effortless monitoring

Nursing staff can focus their time on other important tasks due to the reduction in intermittent blood sampling requirements.

 

Critical Data for Critical Care

 

Critical data

Continuous glucose monitoring (CGM) detects the rapid changes and variability missed by intermittent testing.

This provides real-time blood glucose measurements and reveals trends that enable proactive therapeutic interventions to maintain glycemic control in the target range.

Learn more

 

 

Improving Outcomes, Improving Lives

Several randomized controlled trials, large cohort studies and comprehensive literature reviews have demonstrated that clinical and economic outcomes, including mortality, length of stay and costs of intensive insulin therapy can be improved through better management of blood glucose levels.


Clinical Benefits Economic Impact

 

 

A Better Method

A clinician taking blood from a patient’s finger for glucose measurement.

The practice of glycemic control has been broadly adopted in hospitals worldwide. However, current glucose monitoring is generally performed manually by nursing staff, primarily using finger sticks and hand-held glucose meters.

This intermittent glucose monitoring practice is labor intensive, may offer inadequate accuracy and frequency required to safely maintain patients within a prescribed glucose range, and is not recommended in many critically ill patients.7,8

.

 

References

  1. Krinsley JS, Egi M, Kiss A, et al. Diabetic status and the relation of the three domains of glycemic control to mortality in critically ill patients: an international multicenter cohort study. Crit Care. 2013;17(2):R37+. doi:10.1186/cc12547.
  2. Sechterberger MK, Bosman RJ, Oudemans-van Straaten HM, et al. The effect of diabetes mellitus on the association between measures of glycaemic control and ICU mortality: a retrospective cohort study. Crit Care. 2013;17(2):R52. doi:10.1186/cc12572.
  3. Van den Berghe G, Wouters PJ, Weekers F, et al. Intensive Insulin Therapy in Critically Ill Patients. N Engl J Med. 2001;345(19):1359-1367.
  4. Van den Berghe G, Wilmer A, Hermans G, et al. Intensive Insulin Therapy in the Medical ICU. N Engl J Med. 2006;354:449-461. doi:10.1056/NEJMoa1005372.
  5. Furnary AP, Wu Y. Eliminating the diabetic disadvantage: the Portland Diabetic Project. Semin Thorac Cardiovasc Surg. 2006;18(4):302-308. doi:10.1053/j.semtcvs.2006.04.005.
  6. Krinsley JS. Effect of an intensive glucose management protocol on the mortality of critically ill adult patients. Mayo Clin Proc. 2004;79(8):992-1000. doi:10.4065/79.8.992.
  7. Finfer S, Wernerman J, Preiser J-C, et al. Clinical review: Consensus recommendations on measurement of blood glucose and reporting glycemic control in critically ill adults. Crit Care. 2013;17(3):229. doi:10.1186/cc12537.
  8. Ichai C, Preiser J-C. International recommendations for glucose control in adult non diabetic critically ill patients. Crit Care. 2010;14(5):R166. doi:10.1186/cc9258.